What is ProSci?
ProSci Inc specializes in the development and production of custom polyclonal, monoclonal, and single domain antibodies, primarily for research applications in vaccine design, diagnostics, and therapeutics. The company leverages the unique advantages of rabbit immune systems to generate antibodies with significantly higher binding affinities compared to those derived from other animals. ProSci's expertise extends to tackling complex targets, including small molecules, point mutations, and species-specific orthologs. With over 17 years of experience, ProSci differentiates itself through high-quality technical assistance, competitive pricing, and highly customizable project scopes, ensuring client needs are met at every stage of the research process. Their antibodies have been featured in numerous prestigious scientific publications worldwide.
How much funding has ProSci raised?
ProSci has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in ProSci
PPP
Public-Private Partnership
What's next for ProSci?
The recent strategic investment in ProSci signals a pivotal moment for the company, likely enabling accelerated research and development, expansion of production capabilities, and broader market penetration. This backing is expected to fuel advancements in their custom antibody services, potentially leading to new diagnostic tools and therapeutic candidates. ProSci's focus on challenging targets and its commitment to client-specific solutions position it for sustained growth and innovation within the competitive biotechnology landscape.
See full ProSci company page
